State University of New York at Buffalo

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1846-05-11

Employees: 1K

Market Cap: -

Website: http://www.buffalo.edu

Clinical Trials

24 Hour Ambulatory Cardiac Oxygen Consumption

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Nebivolol/valsartan
Drug: Nebivolol
Drug: Valsartan

First Posted Date: 2021-12-27

Last Posted Date: 2021-12-27

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 26

Registration Number: NCT05170061

Locations: 🇺🇸
Erie County Medical Center, Buffalo, New York, United States

Primary Care Amoxicillin Challenge

Phase 4

Withdrawn

Conditions: Amoxicillin Allergy

Interventions: Drug: Amoxicillin

First Posted Date: 2021-12-21

Last Posted Date: 2023-10-18

Lead Sponsor: State University of New York at Buffalo

Registration Number: NCT05165212

Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication

Not Applicable

Active, not recruiting

Conditions: Chronic Kidney Diseases
End-stage Renal Disease

Interventions: Behavioral: Kidney donation and transplant information made easy

First Posted Date: 2021-12-13

Last Posted Date: 2024-11-26

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 422

Registration Number: NCT05154773

Locations: 🇺🇸
Erie County Medical Center, Buffalo, New York, United States

EMS Providers' Health Initiative Study

Not Applicable

Recruiting

Conditions: Shift-work Disorder

Interventions: Other: Meal service

First Posted Date: 2021-12-10

Last Posted Date: 2024-02-15

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 40

Registration Number: NCT05153759

Locations: 🇺🇸
University at Buffalo, Buffalo, New York, United States

EPPIC: Easing Pelvic Pain Interventions Clinical Research Program

Not Applicable

Recruiting

Conditions: Chronic Pelvic Pain Syndrome
Bladder Pain Syndrome
Urologic Chronic Pelvic Pain Syndrome (UCPPS)
Interstitial Cystitis
Chronic Pain
Chronic Prostatitis
Chronic Overlapping Pain Disorders

Interventions: Behavioral: Patient Education/Support
Behavioral: Minimal Contact-Cognitive Behavior Therapy

First Posted Date: 2021-11-19

Last Posted Date: 2024-11-12

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 240

Registration Number: NCT05127616

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
University at Buffalo (the only clinical site where treatment is delivered), Buffalo, New York, United States

Home-Based Dual-Task Training for Older Adults

Not Applicable

Completed

Conditions: Mild Cognitive Impairment

Interventions: Behavioral: Dual-Task Exercise Training

First Posted Date: 2021-11-04

Last Posted Date: 2023-06-15

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 18

Registration Number: NCT05108246

Locations: 🇺🇸
University at Buffalo, SUNY, Buffalo, New York, United States

Pioglitazone and Insulin Resistance in ADT

Phase 3

Withdrawn

Conditions: Prostate Cancer
Insulin Resistance
Diabetes Mellitus, Type 2
Androgen Deficiency

Interventions: Drug: Placebo
Drug: Pioglitazone 30 mg

First Posted Date: 2021-10-28

Last Posted Date: 2023-08-15

Lead Sponsor: State University of New York at Buffalo

Registration Number: NCT05098327

Locations: 🇺🇸
Diabetes and Endocrinology Research Center of WNY, Buffalo, New York, United States

Bictegravir in the Elderly Living With HIV (BICEP)

Active, not recruiting

Conditions: HIV-1-infection

Interventions: Drug: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]

First Posted Date: 2021-10-01

Last Posted Date: 2024-06-04

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 162

Registration Number: NCT05064020

Locations: 🇺🇸
Evergreen Health, Buffalo, New York, United States

Technology-assisted Conscientiousness Therapy for People With Multiple Sclerosis

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Behavioral: Conscientiousness Coach

First Posted Date: 2021-07-08

Last Posted Date: 2024-10-30

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 60

Registration Number: NCT04953689

Locations: 🇺🇸
Conventus Building, Buffalo, New York, United States

Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

Phase 2

Completed

Conditions: Secondary-progressive Multiple Sclerosis

Interventions: Drug: Ocrevus
Drug: Mayzent

First Posted Date: 2021-06-14

Last Posted Date: 2023-08-14

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 18

Registration Number: NCT04925557

Locations: 🇺🇸
University at Buffalo, Buffalo General Hospital, Buffalo, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy